Physician profile
Joseph G Straley
NPI 1073621900
$552.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $102 · 2021: $57.45 · 2022: $150 · 2023: $104 · 2024: $28.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $246.61 | 2019-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $61.74 | 2022-2024 | Vaxelis, M-M-R II, Gardasil 9 |
| Corium, LLC | $32.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.81 | 2019 | |
| Glaxosmithkline, LLC. | $25.97 | 2023-2024 | Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $25.07 | 2019-2020 | |
| Kaleo, INC. | $24.87 | 2022 | |
| Pfizer INC. | $21.29 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $16.85 | 2022 | |
| Genentech USA, INC. | $15.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.12 | 2019 | |
| Neos Therapeutics, LP | $13.44 | 2020 | |
| Sobi, INC | $13.36 | 2023 | |
| Phadia US INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Straley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.